Iovance Biotherapeutics is trading 11.76% higher at $14.88 on October 9, 2026, with no clear company-specific announcement identified to explain the move.
- The available report likewise noted no new company-specific catalyst.
- The biotech backdrop may be supportive: XBI is up 2.50%, alongside positive IPO and dealmaking sentiment, but this does not establish a direct cause for Iovance’s larger gain.